Update: New drug combination for early treatment of some metastatic prostate cancer
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)Printer Friendly Page Read the Original Article
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2. It may also be relevant for:
- people with metastatic or advanced cancer
- people with a genetic mutation linked to cancer risk
- people with a family history of cancer
- people with castration-resistant prostate cancer
Research Timeline: Post Approval
What is this update about?
The FDA-approved Lynparza in combination with Zytiga () and prednisone (or prednisolone) as a treatment for castration-resistant cancer for people with or mutation found on genetic testing or tumor testing.
This approval is based on the results of a large clinical trial called the PROpel trial. Prior to the study participants had received to treat mCRPC but no other hormonal agents or chemotherapy. Participants were divided into two groups. All participants received Zytiga and prednisone. Half of the participants also received Lynparza and the other half received a sugar pill ().
People who tested positive for a mutation responded especially well to Lynparza plus compared to those who had and . After eight months, people with a or mutation who received Lynparza plus were more likely to survive and less likely to have their cancer progress.
Lynparza is a type of known as a . Like other PARP inhibitors, it can be effective against cancers with mutations in and .
Lynparza () is a pill. The most common side effects, in order of frequency, are:
- Low red blood cells (anemia)
- Decreased appetite
- Low white blood cells (Lymphopenia)
- Stomach pain
In the clinical trial that led to this approval, almost 1 of 5 people taking Lynparza needed to receive at least one blood transfusion. One of 10 required more than one blood transfusion; however, they were still able to continue taking the drug.
What does this mean for me?
If you have castration-resistant cancer (mCRPC), ask your doctor if Lynparza combined with Zytiga might be an option for you. Your doctor may recommend genetic counseling, genetic testing and tumor testing, or genetic testing for a mutation to see if you are eligible for Lynparza. If you have mCRPC and do not have a or you may still benefit from treatment with a . You can find more information here.
approves with and prednisone (or prednisolone) for BRCA-mutated castration-resistant cancer. news release. May 31, 2023.
Disclosure: FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.
Share your thoughts on this XRAY review by taking our brief survey.
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced cancer.
- NCT04592237: Chemotherapy, and for the Treatment of Aggressive Variant Cancer. This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (), and an agents (cetrelimab) works for treating people with a rare type of cancer known as aggressive variant cancer (AVPC).
- NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or in Patients With Castration-Resistant Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with castration-resistant cancer who have been treated with at least 2 prior lines of treatment.
- NCT03317392: Studying the Medication Given with Radium-223 for Advanced Cancer with Bone . This study is measuring the best dosage for and side effects of the drug combination and radium-223 to treat men with mCRPC that has spread to the bones.
- NCT04497844: Treatment for Castration-Sensitive Cancer and Inherited or Tumor Mutations in Damage Repair Genes (Amplitude). The goal of AMPLITUDE is to see if adding to standard of care hormone therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have castration-sensitive cancer and have an inherited or tumor mutation in one of the following genes involved in damage repair: , , , , FANCA,PALB2, RAD51B and RAD54L.
Other clinical trials for people with cancer can be found here.
The following organizations offer peer support services for people with or at high risk for cancer:
- FORCE peer support
- Visit our message boards.
- Once you register, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Sign up for our Peer Navigation Program.
- Users are matched with a volunteer who shares their mutation and situation.
- Join our private Facebook group.
- Find a virtual or in-person support meeting.
- Join a Zoom community group meeting.
- Visit our message boards.
- ZERO-The End of Cancer is a nonprofit organization that provides information and support resources for men with cancer.